- Company
- K-Rare Disease Drug Hunterase that is more popular overseas
- by Chon, Seung-Hyun Nov 8, 2021 05:51am
- Hunterase, developed by GC Pharma, is speeding up its efforts to target global markets. It is successful as a treatment for rare diseases developed in Korea, generating more than three times more sales than domestic demand in overseas markets. According to GC Pharma on the 4th, Hunterase's sales rose 77.7% year-on-year to 23.1 billion won in
- Policy
- The introduction of a double price system is empty talk
- by Lee, Jeong-Hwan Nov 8, 2021 05:51am
- When the government responded that it was introducing a double price system instead of opposing the National Assembly's criticism that incentives such as exclusion and suspension of PVA should be given to new domestic drugs, the domestic pharmaceutical industry negatively evaluated it as an "empty talk-style administration." Critics say that
- Company
- Reimbursement for Olumiant in AD is being discussed
- by Eo, Yun-Ho Nov 5, 2021 05:24am
- Discussions on increasing coverage for atopic dermatitis treatments continue. According to industry sources, the authorities have completed collecting expert opinions on Lilly’s JAK inhibitor ‘Olumiant (baricitinib)’ Sanofi’s ‘Dupixent (dupilumab)’ and is awaiting deliberation by the Health Insurance Review and Assessment Service’s
- Policy
- Taiwanese PharmaEssentia got a business license
- by Lee, Tak-Sun Nov 5, 2021 05:24am
- PharmaEssentia, a Korean subsidiary of PharmaEssentia, a Taiwanese pharmaceutical company, has obtained a drug business license. The first CEO of PharmaEssentia in Korea is Haksun Moon, former representative of Novartis Korea. The MFDS granted PharmaEssentia Korea a drug business license as of the 4th. The first factory is located on the 1
- Company
- LG Chem, developing a new drug that has never existed before
- by Lee, Seok-Jun Nov 5, 2021 05:24am
- LG Chem has started clinical development to develop next-generation osteoarthritis treatments that have not existed before. Osteoarthritis is a degenerative disease that causes pain and gait disorders due to inflammation in the joints and cartilage wear. LG Chem announced on the 4th that it has been approved for phase 1b/2 clinical trials o
- Opinion
- [Reporter’s View] New drugs for Alzheimer’s in development
- by Nov 5, 2021 05:24am
- "I felt like it was all a dream. But I wasn't sure if I was young dreaming that I’m older, or I was old dreaming that I was younger. I have Alzheimer's." This is what Hye-Ja Kim, acting as a dementia patient in the “The Light in Your Eyes” TV drama two years ago, said as she revealed her condition to her friends. The drama gained much a
- Policy
- Gov needs to maintain patient benefits to the public
- by Lee, Jeong-Hwan Nov 5, 2021 05:23am
- Starting next year, the Korea Organization For Patient Group expressed regret to the MOHW and the HIRA, which triggered anxiety and confusion among cancer patients by announcing plans to exclude second-tier anticancer drugs from the coverage. The Korea Organization For Patient Group urged the MOHW and the HIRA to give confidence in ensurin
- InterView
- KYMRIAH, a good but expensive medicine
- by Eo, Yun-Ho Nov 4, 2021 05:56am
- The cost of a single injection is 500 million won, but the era has come when cancer can be expected to be cured with that "once." Ultra-high-priced, high-tech new drugs are already approaching us. Kymriah (Tisagencleucel), a CAR-T treatment called dream anticancer, is the new drug. Kymriah obtained approval from the MFDS in March as the fi
- Policy
- The HIRA proceeds to improve the mediation system
- by Lee, Hye-Kyung Nov 4, 2021 05:56am
- The MOHW requests the promotion of research services for effective system operation. Improvement of the adjustment application system will be carried out to raise the upper limit of -reimbursed drugs. The HIRA recently made an open bid for a "request for research proposal on how to improve the drug adjustment application system" and announced
- Policy
- MFDS to support Phase III trials of domestic COVID-19 Txs
- by Lee, Tak-Sun Nov 4, 2021 05:56am
- The Ministry of Food and Drug Safety has been supporting domestic companies that have entered Phase III trials for their domestic COVID-19 treatments through its ‘Development-focused Support Council.' The three items currently approved for Phase III trials and supported by the Support Council are: Chong Kun Dang’s ‘Nafabeltan (nafamos
